^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

tamoxifen

Company:
Generic mfg.
Drug class:
Estrogen receptor antagonist
18d
Apurinic/apyrimidinic endonuclease 1 prevents oxidative DNA damage in intestinal epithelial cells induced by genotoxic Escherichia coli NC101. (PubMed, Redox Biol)
APE1 protects epithelial cells by inhibiting the accumulation of ROS and oxidative DNA damage induced by intestinal bacteria, including the colibactin produced by E. coli NC101.
Journal
|
APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
|
tamoxifen
18d
Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer. (PubMed, BMC Cancer)
Comprehensive CYP2D6 profiling improves phenotype assignment and highlights methodological pitfalls that may contribute to inconsistencies in pharmacogenetic studies. While no definitive association with clinical outcomes was observed in the overall cohort, these findings underscore the importance of analytically robust genotyping strategies and warrant validation in larger, prospectively designed cohorts, and highlight the importance of comprehensive genotyping strategies in resolving inconsistencies across pharmacogenetic studies.
Journal
|
ER (Estrogen receptor)
|
ER positive
|
tamoxifen
19d
Proximal Tubule-Derived Semaphorin 3C Promotes Fibrosis in Adenine-Induced Tubulointerstitial Nephritis. (PubMed, Kidney360)
PT-derived SEMA3C promotes inflammation and fibrosis in adenine-induced tubulointerstitial nephritis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NDRG1 (N-Myc Downstream Regulated 1)
|
tamoxifen
19d
Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications. (PubMed, JCO Oncol Pract)
Available breast cancer-specific data are largely retrospective and suggest clinically meaningful but attenuated weight loss compared with pivotal obesity trials, with concurrent aromatase inhibitor or tamoxifen use associated with smaller reductions...Studies also suggest potential survivorship benefits relevant to lymphedema and cardio-oncology, although causality is unproven. Prospective cancer-specific trials and implementation studies are needed to define safety; optimal timing; patient selection; and effects on oncologic outcomes, function, and quality of life.
Journal
|
ER (Estrogen receptor) • IGF1 (Insulin-like growth factor 1) • LEP (Leptin)
|
ER positive
|
tamoxifen
19d
The antiproliferative and antimigratory properties of the 3-biotin-B-norcholesteryl benzimidazole derivative in MCF-7 cells are mediated through G1 phase arrest and apoptosis. (PubMed, Steroids)
MTT and colony formation assays identified compound 1 as the most potent antiproliferative agent, with an IC50 of 6.53 μM in MCF-7 cells, which outperformed tamoxifen under identical experimental conditions...Taken together, these observations establish compound 1 as a promising antitumor lead scaffold for subsequent structural modification. Further investigations regarding its selectivity profile, systemic toxicity, pharmacokinetic properties, and in vivo therapeutic efficacy are therefore warranted.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MDM2 (E3 ubiquitin protein ligase) • ANXA5 (Annexin A5)
|
tamoxifen
20d
Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway. (PubMed, J Med Chem)
Herein, we developed drug-conjugated Tam-NHC-gold(I) complexes that can target breast cancer cells by the binding of tamoxifen (Tam) to the G protein-coupled estrogen receptor (GPER) present on cell membranes...Moreover, 7b exhibited potent antiproliferative activity on both wild-type and mutant MCF-7Y537S in xenograft mouse models with low toxicity. This study verified that 7b may offer a new approach for the treatment of endocrine-resistant breast cancer.
Journal
|
ER (Estrogen receptor) • CALCR (Calcitonin Receptor 2)
|
HR positive • ESR1 mutation
|
tamoxifen
23d
An unresectable desmoid tumour demonstrating long-term complete response to imatinib monotherapy: a case report. (PubMed, J Med Case Rep)
We describe a case of complete and durable remission achieved with imatinib monotherapy in an unresectable mesenteric desmoid tumour with the patient remaining disease-free at 10 years. This case highlights the potential for long-term complete response and underscores the need for prospective data to guide treatment duration and cessation criteria.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
imatinib • tamoxifen
23d
Tailoring Oncofertility to Breast Cancer Subtype: A Systematic Review of Fertility Preservation Strategies in Premenopausal Women. (PubMed, Cancers (Basel))
Among studies with medium-term follow-up (3-5.5 years), no significant increase in recurrence or mortality attributable to FP was identified; long-term data beyond 5 years remain sparse. Substantial heterogeneity precluded meta-analysis; all synthesis is narrative. Standardized outco reporting and larger prospective subtype-stratified studies are required to establish precision oncofertility recommendations.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
HER-2 positive • HR positive • HR negative
|
tamoxifen • letrozole
23d
When Breast Cancer Meets the Uterus: A Quantitative Review of 105 Cases Spanning Four Decades. (PubMed, Medicina (Kaunas))
Invasive lobular carcinoma (ILC) demonstrates a documented predilection for unusual metastatic patterns including the female genital tract, while tamoxifen-associated endometrial pathology may complicate diagnosis in breast cancer survivors...Endometrial sampling should be considered with a low threshold in breast cancer survivors with abnormal uterine bleeding, and breast imaging is warranted when discohesive cells are encountered without a known breast primary. These proportions describe the published case literature rather than population-based prevalence; because the evidence is limited to case reports and small series, they should not be read as the true frequency of uterine involvement among women with breast cancer.
Review • Journal
|
CDH1 (Cadherin 1) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TRPS1 (Transcriptional Repressor GATA Binding 1)
|
tamoxifen
24d
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
|
tamoxifen
24d
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
tamoxifen • goserelin acetate • Inluriyo (imlunestrant)
25d
A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer. (PubMed, Bioorg Chem)
We designed 20a, a novel ERα degrader based on the OBHSA scaffold with a hydrophobic amantadine tag. The latter effect creates synthetic lethality with Olaparib. Our findings elucidate the multi-mechanistic antitumor profile of 20a, highlighting its potential as a next-generation therapeutic for endocrine-resistant ERα-positive BC.
Journal
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • ATF4 (Activating Transcription Factor 4)
|
ER positive
|
Lynparza (olaparib) • tamoxifen